Literature DB >> 19474295

Neural deficits contribute to respiratory insufficiency in Pompe disease.

Lara R DeRuisseau1, David D Fuller, Kai Qiu, Keith C DeRuisseau, William H Donnelly, Cathryn Mah, Paul J Reier, Barry J Byrne.   

Abstract

Pompe disease is a severe form of muscular dystrophy due to glycogen accumulation in all tissues, especially striated muscle. Disease severity is directly related to the deficiency of acid alpha-glucosidase (GAA), which degrades glycogen in the lysosome. Respiratory dysfunction is a hallmark of the disease, muscle weakness has been viewed as the underlying cause, and the possibility of an associated neural contribution has not been evaluated previously. Therefore, we examined behavioral and neurophysiological aspects of breathing in 2 animal models of Pompe disease--the Gaa(-/-) mouse and a transgenic line (MTP) expressing GAA only in skeletal muscle, as well as a detailed analysis of the CNS in a Pompe disease patient. Glycogen content was elevated in the Gaa(-/-) mouse cervical spinal cord. Retrograde labeling of phrenic motoneurons showed significantly greater soma size in Gaa(-/-) mice vs. isogenic controls, and glycogen was observed in Gaa(-/-) phrenic motoneurons. Ventilation, assessed via plethysmography, was attenuated during quiet breathing and hypercapnic challenge in Gaa(-/-) mice (6 to >21 months of age) vs. controls. We confirmed that MTP mice had normal diaphragmatic contractile properties; however, MTP mice had ventilation similar to the Gaa(-/-) mice during quiet breathing. Neurophysiological recordings indicated that efferent phrenic nerve inspiratory burst amplitudes were substantially lower in Gaa(-/-) and MTP mice vs. controls. In human samples, we demonstrated similar pathology in the cervical spinal cord and greater accumulation of glycogen in spinal cord compared with brain. We conclude that neural output to the diaphragm is deficient in Gaa(-/-) mice, and therapies targeting muscle alone may be ineffective in Pompe disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474295      PMCID: PMC2695054          DOI: 10.1073/pnas.0902534106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Whole-body plethysmography, does it measure tidal volume of small animals?

Authors:  G Enhorning; S van Schaik; C Lundgren; I Vargas
Journal:  Can J Physiol Pharmacol       Date:  1998 Oct-Nov       Impact factor: 2.273

2.  POMPE'S DISEASE (DIFFUSE GLYCOGENOSIS) WITH NEURONAL STORAGE.

Authors:  E L MANCALL; G E APONTE; R G BERRY
Journal:  J Neuropathol Exp Neurol       Date:  1965-01       Impact factor: 3.685

3.  FUNCTIONAL SIGNIFICANCE OF CELL SIZE IN SPINAL MOTONEURONS.

Authors:  E HENNEMAN; G SOMJEN; D O CARPENTER
Journal:  J Neurophysiol       Date:  1965-05       Impact factor: 2.714

4.  Glycogen disease of skeletal muscle; report of two cases and review of literature.

Authors:  H ZELLWEGER; A DARK; G A ABU-HAIDAR
Journal:  Pediatrics       Date:  1955-06       Impact factor: 7.124

5.  Tissue fractionation studies. 16. Intracellular distribution and properties of alpha-glucosidases in rat liver.

Authors:  N LEJEUNE; D THINES-SEMPOUX; H G HERS
Journal:  Biochem J       Date:  1963-01       Impact factor: 3.857

6.  Glycogen disease resembling mongolism, cretinism, and amytonia congenita; case report and review of literature.

Authors:  D H CLEMENT; G C GODMAN
Journal:  J Pediatr       Date:  1950-01       Impact factor: 4.406

7.  Basic fibroblast growth factor increases long-term survival of spinal motor neurons and improves respiratory function after experimental spinal cord injury.

Authors:  Y D Teng; I Mocchetti; A M Taveira-DaSilva; R A Gillis; J R Wrathall
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

8.  Murine acid alpha-glucosidase: cell-specific mRNA differential expression during development and maturation.

Authors:  E Ponce; D P Witte; R Hirschhorn; M L Huie; G A Grabowski
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

9.  Episodic hypoxia induces long-term facilitation of neural drive to tongue protrudor and retractor muscles.

Authors:  D D Fuller
Journal:  J Appl Physiol (1985)       Date:  2005-01-07

Review 10.  Therapeutic approaches in glycogen storage disease type II/Pompe Disease.

Authors:  Benedikt Schoser; Victoria Hill; Nina Raben
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

View more
  97 in total

1.  36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.

Authors:  Caroline Regnery; Cornelia Kornblum; Frank Hanisch; Stefan Vielhaber; Nicola Strigl-Pill; Birgit Grunert; Wolfgang Müller-Felber; Franz Xaver Glocker; Matthias Spranger; Marcus Deschauer; Eugen Mengel; Benedikt Schoser
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

2.  Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid α-glucosidase.

Authors:  Thomas J Conlon; Kirsten Erger; Stacy Porvasnik; Travis Cossette; Cheryl Roberts; Lynn Combee; Saleem Islam; Jeffry Kelley; Denise Cloutier; Nathalie Clément; Corinne R Abernathy; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2013-09       Impact factor: 5.032

3.  Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice.

Authors:  Kai Qiu; Darin J Falk; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

4.  Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease.

Authors:  Cathryn S Mah; Darin J Falk; Sean A Germain; Jeffry S Kelley; Melissa A Lewis; Denise A Cloutier; Lara R DeRuisseau; Thomas J Conlon; Kerry O Cresawn; Thomas J Fraites; Martha Campbell-Thompson; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2010-01-26       Impact factor: 11.454

Review 5.  Pompe disease gene therapy.

Authors:  Barry J Byrne; Darin J Falk; Christina A Pacak; Sushrusha Nayak; Roland W Herzog; Melissa E Elder; Shelley W Collins; Thomas J Conlon; Nathalie Clement; Brian D Cleaver; Denise A Cloutier; Stacy L Porvasnik; Saleem Islam; Mai K Elmallah; Anatole Martin; Barbara K Smith; David D Fuller; Lee Ann Lawson; Cathryn S Mah
Journal:  Hum Mol Genet       Date:  2011-04-25       Impact factor: 6.150

Review 6.  Multisystem late onset Pompe disease (LOPD): an update on clinical aspects.

Authors:  Antonio Toscano; Carmelo Rodolico; Olimpia Musumeci
Journal:  Ann Transl Med       Date:  2019-07

Review 7.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

8.  Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease.

Authors:  Gaelle Douillard-Guilloux; Nina Raben; Shoichi Takikita; Arnaud Ferry; Alban Vignaud; Isabelle Guillet-Deniau; Maryline Favier; Beth L Thurberg; Peter J Roach; Catherine Caillaud; Emmanuel Richard
Journal:  Hum Mol Genet       Date:  2009-12-03       Impact factor: 6.150

9.  Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.

Authors:  Allison M Keeler; Marina Zieger; Sophia H Todeasa; Angela L McCall; Jennifer C Gifford; Samantha Birsak; Sourav R Choudhury; Barry J Byrne; Miguel Sena-Esteves; Mai K ElMallah
Journal:  Hum Gene Ther       Date:  2018-07-25       Impact factor: 5.695

10.  Altered activation of the diaphragm in late-onset Pompe disease.

Authors:  Barbara K Smith; Manuela Corti; A Daniel Martin; David D Fuller; Barry J Byrne
Journal:  Respir Physiol Neurobiol       Date:  2015-11-28       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.